|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����,�������� |
|
Ƥ������ |
| ��������������� | |
|
���� |
|
�ź��� |
|
����� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
�������Ϳ�������һЩƤ�������о���չ
��С��, �ź���, �����
���ľ�ҽ��ѧ����ҽԺƤ����, ����710032
����������ѧ˵��������ѧ�������о���������ҽѧ��ʵ��Ӧ�ò�������Զ��Ӱ�졣���п������Ϳ���(��Ӱ��)����Ϊ����ҽѧ��ʵ��Ӧ���о��ṩ���µ�˼·�����оͿ������Ϳ�����һЩƤ����(��Ⱦ�Լ����������Լ��������������������Լ�����)�������о��еĽ�չ������������
[2] Polonelli L, Seguy N, Conti S, et al. Monoclonal yeast killer toxinlike candidacidal anti-idiotypic antibodies. Clin Diagn Lab Immunol,1997, 4(2):142-146.
[3] Magliani W, Conti S, Arseni S, et al. Killer anti-idiotypes in the control of fungal infections. Curr Opin Investig Drugs, 2001,2(4):477-479.
[4] Magliani W, Conti S, Cassone A,et al. New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med, 2002, 8 (3):121-126.
[5] Polonelli L, De Bernadis F, Conti S, et al. Human natural yeast killer toxin-like candidacidal antibodies. J Imrnunol, 1996, 156 (5):1880-1885.
[6] Seguy N, Polonelli L, Dei-Cas E, et al. Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. FEMS Immunol Med Microbiol, 1998, 22(1-2):145-149.
[7] Cailliez JC, Seguy N, Aliouat EM, et al. The yeast killer phenomenon:a hypothetical way to control Pneumocystis carinii pneumonia.Med Hypotheses, 1994, 43(3):167-171.
[8] Conti S, Fanti F, Magliani W, et al. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis, 1998, 177(3):807-811.
[9] Conti S, Magliani W, Arseni S,et al. Inhibition by yeast killer toxin-like antibodies of oral Streptococci adhesion to tooth surfaces in an ex vivo model. Mol Med, 2002, 8(6):313-317.
[10] Savoia D, Avanzini C, Conti S, et al. In vitro leishmanicidal activity of a monoclonal antibody mimicking a yeast killer toxin. J Eukaryot Microbiol, 2002, 49(4):319-323.
[11] Cenci E, Mencacci A, Spreca A, et al. Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun, 2002, 70(5):2375-2382.
[12] Conti S, Magliani W, Gerloni M, et al. A transphyletic anti-infectious control strategy based on the killer phenomenon. FEMS Immunol Med Microbiol, 1998, 22(1-2):151-161.
[13] Stadler BM, Starmpfli MR, Miescher S, et al. Biological activities of anti-IgE antibodies. Int Arch Allergy Immunol, 1993, 102 (2):121-126.
[14] Budolf MP, Vogel M, Kricek F, et al. Epitope-specific antibody response to IgE by mimotope immunization. J Inmunol, 1998, 160(7):3315-3321.
[15] Vogel M, Miescher S, Kuhn S, et al. Mimicry of human IgE epitopes by anti-idiotypic antibodies. J Mol Biol, 2000, 298 (5):729-735.
[16] Stadler BM, Zurcher AW, Miescher S, et al. Mimotope and anti-idiotypic vaccines to induce an anti-IgE response. Int Arch Allergy Immunol, 1999, 118(2-4):119-121.
[17] Rudolf MP, Zuercher AW, Nechansky A, et al. Molecular basis for nonanaphylactogenicity of a monoclonal anti-IgE antibody. J Immunol,2000, 165(2):813-819.
[18] Alfonso M, Diaz A, Hernandez AM, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol, 2002, 168 (5):2523-2529.
[19] Bitton RJ, Guthmmn MD, Gabri MR, et al. Cancer vaccines:an update with special focus on ganglioside antigens. Oncol Rep, 2002, 9(2):267-276.
[20] Fishman P, Merimski O, Baharav E, et al. Autoantibodies to tyrosinase:the bridge between melanoma and vitiligo. Cancer, 199, 7(8):1461-1464.
[21] Eivazova ER, McDonnell JM, Sutton B J, et al. Cross-reactivity of antiidiotypic antibodies with DNA in systemic lupus erythematosus. Arthritis Rheum, 2000, 43(2):429-439.
[22] Spertini F, Leimgruber A, Morel B, et al. Idiotypic vaccination with a murine anti-dsDNA antibody:phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheumatol, 1999,26 (12),2602-2608.